Abbott Laboratories (ABT) Financial Analysis & Valuation | Quarter Chart
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products... more
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells he... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $181.48B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Robert Ford |
| IPO Date | 1980-03-17 | CAGR | 6.66% |
| Employees | 115,000 | Website | www.abbott.com |
| Div. Yield | 0.09% | Payout Ratio | 67% |
| Buy Back Yield | 0.04% | Total Yield | 0.13% |
ABT chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $166.02B | P/E | 20.13 | Forward P/E | 17.29 | PEG | -0.71 |
| P/S | 146.03 | P/B | 126.25 | P/CF | 696.93 | P/FCF | 890.91 |
| Sales | $46.59B | Sales 1Y | 8.06% | Sales 3Y | 15.81% | Sales 5Y | 15.79% |
| EPS | $5.21 | EPS 1Y | -61.02% | EPS 3Y | 6.14% | EPS 5Y | -12.64% |
| Sales QoQ | 12.8% | EPS QoQ | -14.52% | Sales QoQ Avg | 3.26% | EPS QoQ Avg | -13.04% |
| Gross Margin | 56.38% | Operating Margin | 18.17% | Profit Margin | 13.91% | ROCE | 8.91% |
| ROA | 6% | ROE | 12% | Altman Z Score | 3.28 | Piotroski Score | 5 |
| Current Ratio | 1.39 | Quick Ratio | 1.01 | Cash Ratio | 0.37 | Op. CF Ratio | 0.07 |
| Debt/Equity | 0.65 | Debt/Assets | 0.31 | Lt Debt/Equity | 0.57 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 23.24 | Inventory Turnover | 2.82 | Asset Turnover | 0.41 | Receivables Turnover | 5.5 |
| Enterprise Value | $166.02B | P/E Ratio | 20.13 |
| Forward P/E | 17.29 | PEG Ratio | -0.71 |
| P/S Ratio | 146.03 | P/B Ratio | 126.25 |
| P/CF Ratio | 696.93 | P/FCF Ratio | 890.91 |
| EPS | $5.21 | EPS Growth 1Y | -61.02% |
| EPS Growth 3Y | 6.14% | EPS Growth 5Y | -12.64% |
| Revenue Growth 1Y | 8.06% | Gross Margin | 56.38% |
| Operating Margin | 18.17% | Profit Margin | 13.91% |
| ROE | 12% | ROA | 6% |
| ROCE | 8.91% | Current Ratio | 1.39 |
| Quick Ratio | 1.01 | Cash Ratio | 0.37 |
| Debt/Equity | 0.65 | Interest Coverage | 23.24 |
| Altman Z Score | 3.28 | Piotroski Score | 5 |
Abbott Laboratories (ABT) valuation & financials
Abbott Laboratories (ABT) has a market capitalization of $181.48B and trades at a price-to-earnings ratio of 20.1. It operates in the Healthcare sector (Medical - Devices).
Abbott Laboratories's revenue grew +8.1% over the last year.
Abbott Laboratories's next earnings report is scheduled for October 21, 2026 before market open (provider scheduled date); analysts estimate EPS of $1.42. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)